Drug Information

General Information
Drug ID
DR00429
Drug Name
Losartan
Synonyms
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol; (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol; 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI); 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol; 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol; 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole; 2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole; CL23623; Cozaar; Cozaar (TN); DUP 89; DuP-753; Hyzaar; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Drug Type
Small molecular drug
Indication High blood pressure [ICD11: BA00] Approved [1]
Therapeutic Class
Antihypertensive Agents
Structure
3D MOL 2D MOL
Formula
C22H23ClN6O
Canonical SMILES
CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
CAS Number
CAS 114798-26-4
Pharmaceutical Properties Molecular Weight 422.9 Topological Polar Surface Area 92.5
Heavy Atom Count 30 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
XLogP
4.3
PubChem CID
3961
PubChem SID
103546496 , 104086517 , 104305027 , 11364607 , 11367169 , 11369731 , 11372014 , 11374749 , 11377893 , 11485629 , 11489493 , 11490813 , 11492940 , 11495527 , 118212888 , 14758375 , 14880416 , 26612696 , 26680690 , 26748956 , 26748957 , 29223075 , 46506538 , 46530544 , 47773674 , 48072880 , 48221855 , 48416186 , 4964191 , 49979780 , 50107496 , 50150720 , 53789286 , 56312013 , 56314181 , 57322070 , 6595486 , 7979808 , 8152487 , 842088 , 85209145 , 85789659 , 91011664 , 92124757 , 92307932 , 9283 , 93166444 , 93617630 , 96024836 , 99375910
ChEBI ID
ChEBI:6541
TTD Drug ID
D0DD0K
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
PEPT1 Transporter Info Peptide transporter 1 Substrate [3]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 100 microM Chinese hamster ovary AA8 cells-MDR1 [4]
P-GP Transporter Info Km = 232 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [2]
P-GP Transporter Info Km = 403.2 microM Madin-Darby canine kidney cells (MDCKII)-MDR1 [2]
References
1 Losartan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
3 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
4 Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.